Citations (51)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Xiulei Chen, Zhen Zhou, Zhong Li & Xiaoyong Xu. (2020) Synthesis and nematicidal activities of 1,2,3-benzotriazin-4-one containing 4,5-dihydrothiazole-2-thiol derivatives against Meloidogyne incognita. Phosphorus, Sulfur, and Silicon and the Related Elements 195:3, pages 194-200.
Read now
Read now
Articles from other publishers (50)
Christophe Le Terrier, Patrice Nordmann, Maxime Bouvier & Laurent Poirel. (2023)
Impact of acquired broad-spectrum β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam β-lactamase inhibitors in
Escherichia coli
. Antimicrobial Agents and Chemotherapy 67:10.
Crossref
Crossref
David Melnick, Angela K. Talley, Vipul K. Gupta, Ian A. Critchley, Paul B. Eckburg, Kamal A. Hamed, Nivedita Bhatt, Gary Moore, Daren Austin, Christopher M. Rubino, Sujata M. Bhavnani & Paul G. Ambrose. (2023) Impact of antibiotic pharmacokinetics in urine on recurrent bacteriuria following treatment of complicated urinary tract infections. Antimicrobial Agents and Chemotherapy 67:10.
Crossref
Crossref
Allen Grace T. Niego, Christopher Lambert, Peter Mortimer, Naritsada Thongklang, Sylvie Rapior, Miriam Grosse, Hedda Schrey, Esteban Charria-Girón, Arttapon Walker, Kevin D. Hyde & Marc Stadler. (2023) The contribution of fungi to the global economy. Fungal Diversity.
Crossref
Crossref
H. Ganesan, V. K. Gupta, M. C. Safir, S. M. Bhavnani, A. K. Talley, D. Melnick & C. M. Rubino. (2023) Population Pharmacokinetic Analyses for Tebipenem after Oral Administration of Pro-Drug Tebipenem Pivoxil Hydrobromide. Antimicrobial Agents and Chemotherapy 67:6.
Crossref
Crossref
Christopher M Parry, Farah N Qamar, Samita Rijal, Naina McCann, Stephen Baker & Buddha Basnyat. (2023) What Should We Be Recommending for the Treatment of Enteric Fever?. Open Forum Infectious Diseases 10:Supplement_1, pages S26-S31.
Crossref
Crossref
Gina Patel, Vipul K. Gupta, Leanne Gasink, Floni Bajraktari, Yang Lei, Akash Jain, Praveen Srivastava & Angela K. Talley. (2023) Effect of an Antacid (Aluminum Hydroxide/Magnesium Hydroxide/Simethicone) or a Proton Pump Inhibitor (Omeprazole) on the Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) in Healthy Adult Subjects. Antimicrobial Agents and Chemotherapy 67:4.
Crossref
Crossref
Tomefa E. Asempa, April M. Bobenchik, Lori Bourassa, Andrew E. Clark, Morgan T. Hatch, Holly K. Huse, Isabella W. Martin, A. Brian Mochon, Erik Munson, Maroun M. Sfeir, Monica Srodon, Yungchou Wang & David P. Nicolau. (2023) Antimicrobial Activity of Tebipenem and Comparators against Enterobacterales from diverse Outpatient Centers and Nursing Homes in the United States. International Journal of Antimicrobial Agents 61:3, pages 106733.
Crossref
Crossref
Zhenfeng Shi, Jie Zhang, Lei Tian, Liang Xin, Chengyuan Liang, Xiaodong Ren & Min Li. (2023) A Comprehensive Overview of the Antibiotics Approved in the Last Two Decades: Retrospects and Prospects. Molecules 28:4, pages 1762.
Crossref
Crossref
Yasmeen Abouelhassan, Andrew J Fratoni, Ashley K Shepard, David P Nicolau & Tomefa E Asempa. (2023) Pharmacokinetics and soft-tissue distribution of tebipenem pivoxil hydrobromide using microdialysis: a study in healthy subjects and patients with diabetic foot infections. Journal of Antimicrobial Chemotherapy 78:1, pages 296-301.
Crossref
Crossref
Aliaa Fouad, Richard Quintiliani, David P Nicolau & Tomefa E Asempa. (2023) Relative bioavailability of crushed tebipenem administered through a nasogastric tube with and without enteral feeding. Journal of Antimicrobial Chemotherapy 78:1, pages 205-208.
Crossref
Crossref
Radhika Arya, Breanna S. Goldner & Andrew F. Shorr. (2022) Novel agents in development for multidrug-resistant Gram-negative infections: potential new options facing multiple challenges. Current Opinion in Infectious Diseases 35:6, pages 589-594.
Crossref
Crossref
Sumanth Gandra, Satoshi Takahashi, Fanny S Mitrani-Gold, Aruni Mulgirigama & Diogo A Ferrinho. (2022) A systematic scoping review of faropenem and other oral penems: treatment of Enterobacterales infections, development of resistance and cross-resistance to carbapenems. JAC-Antimicrobial Resistance 4:6.
Crossref
Crossref
Guilherme da Costa de Souza, Cesar Augusto Roque‐Borda & Fernando R. Pavan. (2022) Beta‐lactam resistance and the effectiveness of antimicrobial peptides against KPC‐producing bacteria. Drug Development Research 83:7, pages 1534-1554.
Crossref
Crossref
Adila Nazli, David L. He, Dandan Liao, Muhammad Zafar Irshad Khan, Chao Huang & Yun He. (2022) Strategies and progresses for enhancing targeted antibiotic delivery. Advanced Drug Delivery Reviews 189, pages 114502.
Crossref
Crossref
Ama Ranasinghe, Andrew Henderson, Kyra Cottrell, Cindy S E Tan, Delaney Burnard, Hideo Kato, David L Paterson & Patrick N A Harris. (2022)
Determining the
in vitro
susceptibility of tebipenem, an oral carbapenem, against third-generation cephalosporin-resistant
Escherichia coli
and
Klebsiella pneumoniae
isolated from bloodstream infections
. JAC-Antimicrobial Resistance 4:5.
Crossref
Crossref
Joanna Goscianska, Aleksander Ejsmont, Anna Stasiłowicz-Krzemień, Szymon Sip & Judyta Cielecka-Piontek. (2022) Enhancing antimicrobial activity of β-lactam antibiotic via functionalized mesoporous carbon-based delivery platforms. Microporous and Mesoporous Materials 343, pages 112160.
Crossref
Crossref
Laiz Campos Pereira, Marcelo Aguiar de Fátima, Valdeene Vieira Santos, Carolina Magalhães Brandão, Izabel Almeida Alves & Francine Johansson Azeredo. (2022) Pharmacokinetic/Pharmacodynamic Modeling and Application in Antibacterial and Antifungal Pharmacotherapy: A Narrative Review. Antibiotics 11:8, pages 986.
Crossref
Crossref
Keith A. Rodvold, Mark H. Gotfried, Vipul Gupta, Amanda Ek, Praveen Srivastava, Angela Talley & Jon Bruss. (2022) Plasma and Intrapulmonary Concentrations of Tebipenem following Oral Administration of Tebipenem Pivoxil Hydrobromide to Healthy Adult Subjects. Antimicrobial Agents and Chemotherapy 66:7.
Crossref
Crossref
Vipul K. Gupta, Gina Patel, Leanne Gasink, Floni Bajraktari, Yang Lei, Akash Jain, Praveen Srivastava & Angela K. Talley. (2022) Bioequivalence of two oral formulations of tebipenem pivoxil hydrobromide in healthy subjects. Clinical and Translational Science 15:7, pages 1654-1663.
Crossref
Crossref
Jens Rosellen & Florian Wagenlehner. (2022) TebipenempivoxilTebipenem pivoxil. Die Urologie 61:7, pages 775-776.
Crossref
Crossref
Scott A. Becka, Elise T. Zeiser, John J. LiPuma & Krisztina M. Papp-Wallace. (2022) The Class A β-Lactamase Produced by Burkholderia Species Compromises the Potency of Tebipenem against a Panel of Isolates from the United States. Antibiotics 11:5, pages 674.
Crossref
Crossref
Gina Patel, Keith A. Rodvold, Vipul K. Gupta, Jon Bruss, Leanne Gasink, Floni Bajraktari, Yang Lei, Akash Jain, Praveen Srivastava & Angela K. Talley. (2022) Pharmacokinetics of Oral Tebipenem Pivoxil Hydrobromide in Subjects with Various Degrees of Renal Impairment. Antimicrobial Agents and Chemotherapy 66:5.
Crossref
Crossref
Zhizeng Sun, Lynn Su, Nicole Cotroneo, Ian Critchley, Michael Pucci, Akash Jain & Timothy Palzkill. (2022) Evaluation of Tebipenem Hydrolysis by β-Lactamases Prevalent in Complicated Urinary Tract Infections. Antimicrobial Agents and Chemotherapy 66:5.
Crossref
Crossref
Silvana Alfei & Anna Maria Schito. (2022) β-Lactam Antibiotics and β-Lactamase Enzymes Inhibitors, Part 2: Our Limited Resources. Pharmaceuticals 15:4, pages 476.
Crossref
Crossref
Paul B. EckburgLori MuirIan A. CritchleySusannah WalpoleHanna KwakAnne-Marie PhelanGary MooreAkash JainTim KeutzerAaron DaneDavid MelnickAngela K. Talley. (2022) Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection. New England Journal of Medicine 386:14, pages 1327-1338.
Crossref
Crossref
Elena Fernández Álvaro, Phat Voong Vinh, Cristina de Cozar, David R Willé, Beatriz Urones, Alvaro Cortés, Alan Price, Nhu Tran Do Hoang, Tuyen Ha Thanh, Molly McCloskey, Shareef Shaheen, Denise Dayao, Jaime de Mercado, Pablo Castañeda, Adolfo García-Perez, Benson Singa, Patricia Pavlinac, Judd Walson, Maria Santos Martínez-Martínez, Samuel LM Arnold, Tzipori Saul, Lluis Ballell Pages & Stephen Baker. (2022) The repurposing of Tebipenem pivoxil as alternative therapy for severe gastrointestinal infections caused by extensively drug-resistant Shigella spp. eLife 11.
Crossref
Crossref
Mark S. Butler, Valeria Gigante, Hatim Sati, Sarah Paulin, Laila Al-Sulaiman, John H. Rex, Prabhavathi Fernandes, Cesar A. Arias, Mical Paul, Guy E. Thwaites, Lloyd Czaplewski, Richard A. Alm, Christian Lienhardt, Melvin Spigelman, Lynn L. Silver, Norio Ohmagari, Roman Kozlov, Stephan Harbarth & Peter Beyer. (2022) Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed. Antimicrobial Agents and Chemotherapy 66:3.
Crossref
Crossref
Maria F Mojica, Maria-Agustina Rossi, Alejandro J Vila & Robert A Bonomo. (2022) The urgent need for metallo-β-lactamase inhibitors: an unattended global threat. The Lancet Infectious Diseases 22:1, pages e28-e34.
Crossref
Crossref
Thomas P. Lodise, Teena Chopra, Brian H. Nathanson & Katherine Sulham. (2021) Hospital admission patterns of adult patients with complicated urinary tract infections who present to the hospital by disease acuity and comorbid conditions: How many admissions are potentially avoidable?. American Journal of Infection Control 49:12, pages 1528-1534.
Crossref
Crossref
Balaji Veeraraghavan, Yamuna Devi Bakthavatchalam & Rani Diana Sahni. (2021) Oral Antibiotics in Clinical Development for Community-Acquired Urinary Tract Infections. Infectious Diseases and Therapy 10:4, pages 1815-1835.
Crossref
Crossref
Elli Mylona, Phat Voong Vinh, Sonia Qureshi, Abhilasha Karkey, Sabina Dongol, Tuyen Ha Thanh, Judd Walson, Lluis Ballell, Elena Fernández Álvaro, Farah Qamar & Stephen Baker. (2021)
Tebipenem as an oral alternative for the treatment of typhoid caused by XDR
Salmonella
Typhi
. Journal of Antimicrobial Chemotherapy 76:12, pages 3197-3200.
Crossref
Crossref
Pengxuan Xi, Wanxue Cao, Li Li, Weimin Shi, Fuxin Li, Haitao Xu, Xiaojie Xu, Yu Ke & Jianye Zhang. (2021) Identification of related impurities in an oral pharmaceutical formulation of tebipenem pivoxil using ultra‐high‐performance liquid chromatography/electrospray ionization quadrupole time‐of‐flight tandem mass spectrometry. Rapid Communications in Mass Spectrometry 35:16.
Crossref
Crossref
Robert E. Trout, Allison Zulli, Eugen Mesaros, Randy W. Jackson, Steven Boyd, Bin Liu, Jodie Hamrick, Denis Daigle, Cassandra L. Chatwin, Kaitlyn John, Lisa McLaughlin, Susan M. Cusick, William J. Weiss, Mark E. Pulse, Daniel C. Pevear, Greg Moeck, Luigi Xerri & Christopher J. Burns. (2021) Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes. Journal of Medicinal Chemistry 64:14, pages 10155-10166.
Crossref
Crossref
Guillermo Bahr, Lisandro J. González & Alejandro J. Vila. (2021) Metallo-β-lactamases in the Age of Multidrug Resistance: From Structure and Mechanism to Evolution, Dissemination, and Inhibitor Design. Chemical Reviews 121:13, pages 7957-8094.
Crossref
Crossref
Zeyun Li, Mei Su, Weiyan Cheng, Jueyu Xia, Shuaibing Liu, Ruijuan Liu, Suke Sun, Luyao Feng, Xueya Zhu, Xiaojian Zhang, Xin Tian & Lingbo Qu. (2021) Pharmacokinetics, Urinary Excretion, and Pharmaco-Metabolomic Study of Tebipenem Pivoxil Granules After Single Escalating Oral Dose in Healthy Chinese Volunteers. Frontiers in Pharmacology 12.
Crossref
Crossref
Vipul K. Gupta, Gary Maier, Paul Eckburg, Lisa Morelli, Yang Lei, Akash Jain, Erika Manyak & David Melnick. (2021) Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study of the Effects of Tebipenem Pivoxil Hydrobromide on QT/QTc Intervals in Healthy Subjects. Antimicrobial Agents and Chemotherapy 65:7.
Crossref
Crossref
Donald J. AbrahamSebastian A. Testero, Leticia I. Llarrull, Jed F. Fisher & Shahriar Mobashery. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
188
.
Nicholas P. Clayton, Akash Jain, Stephanie A. Halasohoris, Lisa M. Pysz, Sanae Lembirik, Steven D. Zumbrun, Christopher D. Kane, Michael J. Hackett, Denise Pfefferle, M. Autumn Smiley, Michael S. Anderson, Henry Heine, Gabriel T. Meister & Michael J. Pucci. (2021)
In Vitro
and
In Vivo
Characterization of Tebipenem, an Orally Active Carbapenem, against Biothreat Pathogens
. Antimicrobial Agents and Chemotherapy 65:5.
Crossref
Crossref
Xiaoyong Xu, Xiulei Chen, Gaolei Wang, Jingwei Zhang, Youxin Xiao, Hongfeng Shen, Yaning Chang, Wei Li, Haowu Jia, Ruifeng Zhang & Xiaofeng Cao. 2021. Recent Highlights in the Discovery and Optimization of Crop Protection Products. Recent Highlights in the Discovery and Optimization of Crop Protection Products
335
356
.
Lidia Moreira Lima, Bianca Nascimento Monteiro da Silva, Gisele Barbosa & Eliezer J. Barreiro. (2020) β-lactam antibiotics: An overview from a medicinal chemistry perspective. European Journal of Medicinal Chemistry 208, pages 112829.
Crossref
Crossref
Boris Garber & Jonathan Glauser. (2020) Recent Developments in Infectious Disease Chemotherapy: Review for Emergency Department Practitioners 2020. Current Emergency and Hospital Medicine Reports 8:3, pages 116-121.
Crossref
Crossref
Archana Mahalingam. (2020) Tebipenem: A Novel Oral Carbapenem. Pediatric Infectious Disease 2:1, pages 25-28.
Crossref
Crossref
Nicole Cotroneo, Aileen Rubio, Ian A. Critchley, Chris Pillar & Michael J. Pucci. (2020)
In Vitro
and
In Vivo
Characterization of Tebipenem, an Oral Carbapenem
. Antimicrobial Agents and Chemotherapy 64:8.
Crossref
Crossref
Mehmet Akif Gun, Bulent Bozdogan & Ahmet Yilmaz Coban. (2020) Tuberculosis and beta-lactam antibiotics. Future Microbiology 15:10, pages 937-944.
Crossref
Crossref
Antonela R. Palacios, María-Agustina Rossi, Graciela S. Mahler & Alejandro J. Vila. (2020) Metallo-β-Lactamase Inhibitors Inspired on Snapshots from the Catalytic Mechanism. Biomolecules 10:6, pages 854.
Crossref
Crossref
Jacqueline T. Bork, Alissa Werzen, Rohini Davé, Daniel J. Morgan, Rohit Talwani & Brooke Decker. (2020) Improving Antimicrobial Use in Adult Outpatient Clinics: the New Frontier for Antimicrobial Stewardship Programs. Current Infectious Disease Reports 22:5.
Crossref
Crossref
David L. Paterson, Burcu Isler & Adam Stewart. (2020) New treatment options for multiresistant gram negatives. Current Opinion in Infectious Diseases 33:2, pages 214-223.
Crossref
Crossref
David L. Paterson, Andrew Henderson & Patrick N.A. Harris. (2020) Current evidence for therapy of ceftriaxone-resistant Gram-negative bacteremia. Current Opinion in Infectious Diseases 33:1, pages 78-85.
Crossref
Crossref
Siqi Xue, Zhiying Qin, Guanghui Ren, Zhongjie Yang, Yang Lu, Yongjie Zhang, Ning Li, Xijing Chen & Di Zhao. (2019) A validated UPLC-MS/MS method for determination of tebipenem in human plasma and its application to a pharmacokinetic study in healthy volunteers. Journal of Pharmaceutical and Biomedical Analysis 170, pages 30-39.
Crossref
Crossref
Evelyne Lacasse, Eric Brouillette, Audrey Larose, Thomas R. ParrJr.Jr., Aileen Rubio & François Malouin. (2019)
In Vitro
Activity of Tebipenem (SPR859) against Penicillin-Binding Proteins of Gram-Negative and Gram-Positive Bacteria
. Antimicrobial Agents and Chemotherapy 63:4.
Crossref
Crossref